IBRX has been in the news 462% more than usual
Feb 27, 2026, 7:33 AM
4.82%
What does IBRX do
ImmunityBio is a San Diego-based clinical stage immunotherapy company with 628 employees, focusing on therapies for urologic cancers and infectious diseases. Its lead product candidate, Anktiva, is an IL-15 superagonist fusion protein.
IBRX has been in the news recently: ImmunityBio Inc. experienced fluctuations in its stock prices despite significant revenue growth, while also completing enrollment for its trial testing Anktiva combined with BCG for treating non-muscle invasive bladder cancer. In the broader context of cancer research, Oncolytics Biotech Inc. anticipates FDA approval for pelareorep, which has a 33% response rate in difficult-to-treat colorectal cancer patients.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.